Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
188 hedge funds and large institutions have $1.74B invested in Intercept Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 68 increasing their positions, 50 reducing their positions, and 39 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 50
4% less funds holding
Funds holding: 196 → 188 (-8)
14% less call options, than puts
Call options by funds: $104M | Put options by funds: $122M
18% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 39
18% less capital invested
Capital invested by funds: $2.13B → $1.74B (-$388M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$21.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$14.5M |
| 3 |
JP Morgan Chase
New York
|
+$12M |
| 4 |
ECP
Elk Creek Partners
Denver,
Colorado
|
+$10.8M |
| 5 |
BlackRock
New York
|
+$9.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$40.5M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$30.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$26.5M |
| 4 |
SC
Samlyn Capital
New York
|
-$18M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$14.1M |
ICPT Hedge Fund Activity: Q3 2019 in Review
188 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q3 2019, worth a combined $1.74B — down 18% from $2.13B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of ICPT and 32 opened new positions — a net loss of 7 holders — while 50 trimmed existing stakes and 68 added.
The largest buyer was Macquarie Group, adding an estimated $21.7M. The largest seller was Citadel Advisors, cutting an estimated $40.5M.
- 188 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q3 2019, down from 196 in Q2 2019.
- Funds reported $1.74B of Intercept Pharmaceuticals, Inc. stock for Q3 2019, down 18% quarter-over-quarter.
- 32 funds opened new Intercept Pharmaceuticals, Inc. positions in Q3 2019 and 39 closed out, a net change of -7 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q3 2019 was Macquarie Group, an estimated $21.7M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q3 2019 was Citadel Advisors, an estimated $40.5M sold.
Based on aggregated 13F filings for Q3 2019.